Annals of Oncology : Impact Factor & More
eISSN: 1569-8041pISSN: 0923-7534
Share this on:
Aims and Scope of Annals of Oncology
The Annals of Oncology is a peer-reviewed medical journal of oncology, published by Elsevier. It is the official journal of the European Society for Medical Oncology. The editor-in-chief is Fabrice André (Villejuif, France). Previous editors were Jean-Charles Soria, Jan Vermorken, David J. Kerr and Franco Cavalli. Less
Key Metrics
CiteScore 
47.3
Eigenfactor
0.1 - 0.5
Impact Factor
>= 25
Scite Index
0.88 5-Year SI
SJR
Q1Oncology
SNIP
6.79
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Annals of Oncology
Annals of Oncology Journal Specifications
| Overview | |
| Publisher | ELSEVIER |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1990 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Annals of Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Annals of Oncology
Corrigendum to 'Subcutaneous versus intravenous nivolumab for renal cell carcinoma': [Annals of Oncology volume 36 (2025) 99-107
- 6 May 2026
- Annals of oncology : official journal of the European Society for Medical Oncology
A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study.
- 6 May 2026
- Annals of oncology : official journal of the European Society for Medical Oncology
Survival outcomes in POD1UM-303/InterAACT-2: a phase 3 study of retifanlimab plus carboplatin-paclitaxel in first-line advanced squamous anal cancer.
- 5 May 2026
- Annals of oncology : official journal of the European Society for Medical Oncology
CtDNA-guided immunotherapy following radical cystectomy for muscle-invasive bladder cancer: results from the TOMBOLA trial.
- 1 May 2026
- Annals of oncology : official journal of the European Society for Medical Oncology
Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
- 1 May 2026
- Annals of oncology : official journal of the European Society for Medical Oncology
Is more always better? Low-dose pembrolizumab as a practical step toward more equitable triple-negative breast cancer care.
- 1 May 2026
- Annals of oncology : official journal of the European Society for Medical Oncology
Corrigendum to 'Subcutaneous versus intravenous nivolumab for renal cell carcinoma': [Annals of Oncology volume 36 (2025) 99-107
- 6 May 2026
- Annals of oncology : official journal of the European Society for Medical Oncology
A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study.
- 6 May 2026
- Annals of oncology : official journal of the European Society for Medical Oncology
Survival outcomes in POD1UM-303/InterAACT-2: a phase 3 study of retifanlimab plus carboplatin-paclitaxel in first-line advanced squamous anal cancer.
- 5 May 2026
- Annals of oncology : official journal of the European Society for Medical Oncology
CtDNA-guided immunotherapy following radical cystectomy for muscle-invasive bladder cancer: results from the TOMBOLA trial.
- 1 May 2026
- Annals of oncology : official journal of the European Society for Medical Oncology
Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
- 1 May 2026
- Annals of oncology : official journal of the European Society for Medical Oncology
Is more always better? Low-dose pembrolizumab as a practical step toward more equitable triple-negative breast cancer care.
- 1 May 2026
- Annals of oncology : official journal of the European Society for Medical Oncology
FAQs on Annals of Oncology
How long has Annals of Oncology been actively publishing? 
What is the publishing frequency of Annals of Oncology?
How many articles did Annals of Oncology publish last year?
What is the eISSN & pISSN for Annals of Oncology?
What is Citescore for Annals of Oncology?
What is SNIP score for Annals of Oncology?
What is the SJR for Annals of Oncology?
Who is the publisher of Annals of Oncology?
